Research & development increased 26.0%
Research & development changed +26.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$2.5M→$3.1M4 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +26.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Cash & equivalents changed +272.2% from the comparable as-filed period.
Operating income changed -9.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.